Lexaria Bioscience Corp. LEXX Archives - Page 3 of 39

ThursdayJun 27, 2024 3:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes… The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and…

MondayJun 24, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July

Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration The study’s main objective is to evaluate Lexaria’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug, semaglutide, currently commercially available as Rybelsus(R) The commencement of the pilot study shows Lexaria’s commitment to its promise to focus on GLP-1 studies for 2024, along with its confidence in its…

MondayJun 17, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study

Lexaria, a global innovator in drug delivery platforms, recently announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study The study, a randomized, crossover investigation, will evaluate a dual-action glucagon-like peptide 1 (“GLP-1”) + glucose-dependent insulintropic peptide (“GIP”) It will measure absorption, tolerability, pharmacokinetics, and blood sugar levels Lexaria is counting on its patented DehydraTECH technology for significant growth in the 2024 calendar year, and the study reflects this commitment Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human…

ThursdayJun 06, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide

Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24 The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships Lexaria Bioscience (NASDAQ: LEXX),…

WednesdayJun 05, 2024 2:53 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates completion of the final arm of the study, GLP-1-H24-2, in July. A three-arm, crossover investigation that compares three 7 mg semaglutide dose formulations, the study evaluates three doses: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsule; and for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. The study is designed to measure tolerability and side effects as well…

TuesdayMay 28, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8% Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 (https://ibn.fm/74Pee). This follows the recent…

WednesdayMay 22, 2024 1:29 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received two new patent awards, bringing the company’s patent portfolio to 43 granted patents worldwide. According to the announcement, the company has been granted a patent in its patent family #21, “Compositions and Methods for Treating Hypertension.” The company noted that this is the third granted U.S. patent in this category and is regarding the company’s DehydraTECH(TM)-processed cannabidiol (“CBD”) and evidence of its ability to lower blood pressure in both acute dosing in hypertension as well as during a five-week study duration. In addition, Lexaria has received a granted patent…

FridayMay 17, 2024 2:44 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol (“CBD”), both alone and in combination in diabetic preconditioned rats. According to the announcement, several new areas of investigation are being explored in this study, including evaluating whether DehydraTECH-processed oral GLP-1 drugs are more effective than non-DehydraTECH-processed oral GLP-1 drugs in reaching brain tissue, improving weight loss and improving control of blood sugar. The study will also evaluate…

ThursdayMay 16, 2024 3:16 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growing Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption compared to standard industry formulations, as well as reduce time of onset and deliver drugs more effectively across the blood-brain barrier. “DehydraTECH has a number of potential pharmaceutical applications, a testament to its versatility and overall effectiveness. The key factor that has played a role in its adoption is its unique ability to improve drug bioavailability, a critical marker and determinant of overall drug effectiveness,” a recent article reads. “With this technology, Lexaria…

TuesdayMay 14, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners with the National Research Council of Canada for DehydraTECH-GLP-1 Mode of Action Investigation

Lexaria, a global innovator in drug delivery platforms, just announced its newest relationship with the National Research Council of Canada (“NRC”) Specific molecular characteristics of the glucagon-peptide 1 (“GLP-1”) drug, semaglutide, processed with Lexaria’s patented DehydraTECH(TM) technology, will be evaluated Previous research has shown that using a DehydraTECH-semaglutide capsule composition yields a 43% higher peak level of semaglutide in blood compared to Rybelsus(R). This has potential for increased weight-loss and diabetic control Lexaria’s management is confident that this partnership will complement the company’s animal and human pharmacokinetic and pharmacodynamic studies for the 2024 calendar year Lexaria Bioscience (NASDAQ: LEXX), a…

Site Search

Company Search

Tag: Lexaria Bioscience Corp. LEXX